Boston Scientific (BSX) Stock: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$42.69
0.26 (0.61%)
â˛
5d:
-7.22%
30d:
-2.2%
90d:
-8.65%
WAIT
LOW Confidence
Analysis Updated: Oct 29, 2026 12:00 AM ET
Earnings: Oct 28, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 28, 2026 at $42.41 · last confirmed Oct 29, 2026
Strength: 6.9/10
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BSX is fairly priced but lacks strong directional signals. At -9.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BSX is fairly priced but lacks strong directional signals. At -9.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$72.48
Based on 4.7% avg growth
INTRINSIC VALUE TODAY
$45.00
5.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $42.69, which is considered slightly low relative to its 30-day fair value range of $42.66 to $45.04. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.6) compared to its historical average (17.1). Remarkably, the market is currently pricing in an annual earnings decline of 9.5% over the next few years. This pessimistic expectation contrasts with the company's recent 15.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a uptrend. Immediate support is located at $39.57, while resistance sits at $46.55.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $57.34 (+34.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BSX is in a uptrend. Immediate support is located at $39.57, while resistance sits at $46.55.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $57.34 (+34.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$42.66 -
$45.04
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding BSX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.3% below Wall St target ($57.34)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$42.66 -
$45.04
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$39.57
Resistance Level
$46.55
Current Trend
Uptrend
Technical data as of
Oct 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.64
Wall Street Target
$57.34
(+34.3%)
Revenue Growth (YoY)
7.5%
Earnings Growth (YoY)
15.1%
Profit Margin
17.5%
Valuation Discount vs History
-9.5% cheaper
PE vs Historical
12.6 vs 17.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.5%
(market-implied from PE analysis)
1-Year Target
$38.63
(-10%)
2-Year Target
$34.96
(-18%)
3-Year Target
$31.64
(-26%)
3-Yr Target (if PE normalizes)
(PE: 13â17)
$42.80
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 5.3%)
$78.35
(+84%)
Base:
(SPY PE: 12.6, Growth: 5.3%)
$49.87
(+17%)
Bear:
(PE: 10.7, Growth: 5.3%)
$42.39
(-1%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 17.90 | Current EPS (TTM): $2.37
Bull Case
$66.50
(+56%)
Analyst growth 42.5%, PE expands to 19.7
Base Case
$60.46
(+42%)
Market implied 42.5%, PE stable at 17.9
Bear Case
$28.85
(-32%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.6 to 17.1
Stabilization Target:
$57.74
(+35.3%)
PE Expansion Potential:
+35.3%
Share & Embed Analysis
Last updated: October 30, 2026 1:32 AM ET
Data refreshes hourly during market hours. Next update: 2:32 AM
Data refreshes hourly during market hours. Next update: 2:32 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$119 | 55 HOLD |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 53 HOLD |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$167 | 31 SELL |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 38 SELL |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
